Technical Analysis for GLYC - GlycoMimetics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical GLYC trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bullish Engulfing | Bullish | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | 3.95% | |
Wide Bands | Range Expansion | 3.95% | |
Below Lower BB | Weakness | 3.95% | |
Down 3 Days in a Row | Weakness | 3.95% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Rose Above Previous Day's High | about 16 hours ago |
Rose Above Lower Bollinger Band | about 16 hours ago |
Up 5% | about 16 hours ago |
Up 3% | about 16 hours ago |
Up 2% | about 16 hours ago |
Get a Trading Assistant
- Earnings date: 03/02/2021
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Industry Diseases Drug Discovery Chemotherapy Clinical Trial Acute Myeloid Leukemia Product Testing Sickle Cell Disease Pseudomonas Hematologic Cancers Nursing Research
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.1899 |
52 Week Low | 2.37 |
Average Volume | 921,049 |
200-Day Moving Average | 3.61 |
50-Day Moving Average | 3.38 |
20-Day Moving Average | 3.05 |
10-Day Moving Average | 2.94 |
Average True Range | 0.22 |
ADX | 21.79 |
+DI | 17.53 |
-DI | 31.60 |
Chandelier Exit (Long, 3 ATRs ) | 2.95 |
Chandelier Exit (Short, 3 ATRs ) | 3.10 |
Upper Bollinger Band | 3.58 |
Lower Bollinger Band | 2.53 |
Percent B (%b) | 0.1 |
BandWidth | 34.54 |
MACD Line | -0.18 |
MACD Signal Line | -0.14 |
MACD Histogram | -0.0404 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.92 | ||||
Resistance 3 (R3) | 2.91 | 2.81 | 2.87 | ||
Resistance 2 (R2) | 2.81 | 2.74 | 2.81 | 2.85 | |
Resistance 1 (R1) | 2.72 | 2.69 | 2.77 | 2.73 | 2.84 |
Pivot Point | 2.62 | 2.62 | 2.64 | 2.62 | 2.62 |
Support 1 (S1) | 2.53 | 2.55 | 2.58 | 2.54 | 2.42 |
Support 2 (S2) | 2.43 | 2.50 | 2.43 | 2.41 | |
Support 3 (S3) | 2.34 | 2.43 | 2.39 | ||
Support 4 (S4) | 2.35 |